WithdrawnPhase 1/2

BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma

Stopped: Funding unavailable

United States0Started 2025-11

Plain-language summary

The purpose of this study is to test the safety and efficacy of an investigational (experimental) product called BC3402. This product is considered experimental because it is not approved by the U.S. Food and Drug Administration (FDA).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Hemoglobin ≥9 g/dL
✓. Absolute neutrophil count ≥1000/μL
✓. Platelet count ≥75000/μL
✓. Total bilirubin (TBL) ≤2.0×ULN
✓. AST and ALT ≤5×ULN
✓. Albumin ≥2.8 g/dL
✓. International normalized ratio (INR) ≤1.6
✓. Calculated creatinine clearance ≥45 mL/minute as determined by Cockcroft-Gault (using actual body weight) or 24-hour urine creatinine clearance

What they're measuring

Overall response rate(ORR) per RECIST v1.1

Timeframe: From registration up to 2 years post end of treatment(EOT) or study closure

Trial details

NCT IDNCT06608940

SponsorCase Comprehensive Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-01-01

View on ClinicalTrials.gov More Hepato Cellular Carcinoma (HCC) trials